performed a genome‐wide meta‐analysis and identified five potential susceptibility sites (GCKR, TR1B1, MAU2/TM6SF2, APOE, and PNPLA3) and the potential effects of LPL expression and FTO genotypes on NAFLD.62 This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.